Fig. 3

Allergen-specific IgE, IgG1 and IgG2a levels in serum determined by ELISA. a, b Allergen-specific IgE in SCIT groups. c, d Allergen-specific IgE in OIT groups. e, f Allergen-specific IgG1 in SCIT groups. g, h Allergen-specific IgG1 in OIT groups. i, j Allergen-specific IgG2a in SCIT groups. k, l Allergen-specific IgG2a in OIT groups. Data are represented as mean ± SEM n = 6–8 mice/group. Statistical analysis was performed on each individual time point using one-way ANOVA and Dunnett’s post hoc test for multiple comparisons. All treatment groups were compared to the sensitized control group and significant differences were indicated with letters e.g. ^aP < 0.05; ^aaP < 0.01; ^aaaP < 0.001; ^aaaaP < 0.0001. In CMA figures: a for SCIT 2.5 μg and OIT 0.1 mg, b for SCIT 10 μg and OIT 1 mg, c for SCIT 25 μg and OIT 10 mg, d for OIT 100 mg and s for sham control. In PNA figures: a for SCIT 1 μg and OIT 0.15 mg, b for SCIT 10 μg and OIT 1.5 mg and c for SCIT 100 μg and OIT 15 mg and s for sham control. OIT oral immunotherapy, SCIT subcutaneous immunotherapy, IT immunotherapy, PE peanut extract, id intradermal challenge, ig intragastric challenge, ip intraperitoneal challenge